Cytokinetics says heart disease drug more effective than standard-of-care, shares jump

Cytokinetics, Incorporated

02/09/2025 17:37

Updates

** Shares of drug developer Cytokinetics CYTK.O rise as much as 40.4% to an over six-month high of $49.60

** Stock set for its best day in nearly two years if gains hold

** On Saturday, co said its experimental drug, aficamten, outperformed standard-of-care treatment, metoprolol, in improving heart function and symptoms in obstructive hypertrophic cardiomyopathy patients

** Over half of aficamten-treated patients showed better physical ability and quality of life, co said

** Co plans to seek expanded approval next year, with an FDA decision expected by December

** Obstructive hypertrophic cardiomyopathy is a genetic condition where thickened heart muscle blocks blood flow, and can lead to cardiac arrest

** Including session's move, stock up 2.8% YTD

(Reporting by Kamal Choudhury and Puyaan Singh in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))